Report Overview

The sexual disorder pharmacotherapy market is dominated by drugs indicated for erectile dysfunction which commands an estimated 78% of the total sexual disorder market valued at US$3 billion. Significant market opportunities are evident for the expansion of androgenic therapies to treat sexual disorders in new population groups such as in women with hypoactive sexual desire disorder and in male andropause. Furthermore, new drugs are on course to redefine the landscape of sexual medicine by offering novel therapies for premature ejaculation and specific desire-arousal disorders. Emerging drug treatments targeting the unmet needs of women with sexual disorders are poised to revolutionize the market for sexual dysfunction, and Spectra predicts that the female sexual dysfunction sector may outperform those therapies indicated for male sexual disorders within a decade of availability. However, as a relatively young and controversial therapy area, new drugs for sexual disorders are subject to intense regulatory scrutiny and navigating through the drug approval process is challenging particularly for new sexual disorder indications, which is evident from recent market authorization setbacks for Proctor & Gamble's Intrinsa for female hypoactive sexual desire disorder and Johnson & Johnson/Alza's Dapoxetine for premature ejaculation. However, in this report, The World Market for Sexual Disorders, 2005-2012: Traversing New Frontiers in Sexual Chemistry, the reader will be introduced to a specialty pharmaceutical market that is transitioning to a dynamic, high-value therapy area estimated to exceed US$6.6 billion by 2012.

The report provides a detailed analysis of the sexual disorders therapy area to include insights for product extension and reformulation, sales forecasts to 2012, and impact of late-stage pipeline drugs on the market. An overview of R&D programs within the field is also highlighted showing products from preclinical to premarket authorization phases of development, with promising agents further discussed from commercial and drug development perspectives. Therapy area forecasting and illustrative market data and analysis is also presented to offer insights into potential top-performing products. Therapy area forecasting to 2020 also enables the reader to make key assumptions about future markets and prospects, and utilize the data for proprietary predictive market modelling.